Pfizer, Medivation Halt Alzheimer’s Pact | Chemical & Engineering News
Volume 90 Issue 4 | p. 14 | Concentrates
Issue Date: January 23, 2012

Pfizer, Medivation Halt Alzheimer’s Pact

Department: Business
Keywords: Alzheimer’s, pharmaceuticals, clinical trials

Pfizer and Medivation are ending their collaboration for the Alzheimer’s disease drug candidate dimebon and discontinuing development of the compound. The news comes after a Phase III study showed that giving the drug in combination with Pfizer’s Aricept did not improve cognitive ability or daily functioning in people with Alzheimer’s disease. In 2008, Pfizer paid $225 million for access to dimebon and agreed to pay Medivation upward of $500 million as the drug candidate progressed. The big pharma firm also took on 60% of the development expenses for the failed drug.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment